KDM6B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL258224	0.59	9/20
SCHEMBL82604	0.59	9/20
SCHEMBL480991	0.59	8/20
SCHEMBL116060	0.55	8/20
SCHEMBL547927	0.55	8/20
SCHEMBL535569	1.00	7/20
SCHEMBL71335	0.65	7/20
SCHEMBL115648	0.56	7/20
SCHEMBL188821	0.55	7/20
SCHEMBL310314	0.55	7/20
SCHEMBL123203	0.51	7/20
SCHEMBL258369	0.51	7/20
SCHEMBL535637	0.51	7/20
SCHEMBL115797	0.59	6/20
SCHEMBL116912	0.59	6/20
SCHEMBL591448	0.58	6/20
SCHEMBL258230	0.53	6/20
SCHEMBL587140	0.50	6/20
SCHEMBL115907	0.53	5/20
SCHEMBL167219	0.50	5/20

Clinical trials — most relevant to KDM6B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation	PHASE2	UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia	PHASE1	RECRUITING
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Safety and Pharmacokinetic Profile of CKD-581	PHASE1	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
The Danish TURNER Cryopreservation Study	nan	RECRUITING
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer	nan	UNKNOWN
MIF Involvement in AML	nan	ACTIVE_NOT_RECRUITING
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
The Crosstalk Between the Epigenome and Mitochondria in SCI	nan	NOT_YET_RECRUITING
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19	nan	COMPLETED
COPENHAGEN Minipuberty Study	nan	UNKNOWN
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test	nan	UNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Mechanisms of Immune Deficiency	nan	UNKNOWN
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy	nan	COMPLETED
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia	nan	UNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a KDM6B binder may also engage these)

Protein	Name	Similarity
Q5NCY0	—	1.000	Q5NCY0 →
TET3	Methylcytosine dioxygenase TET3	0.994	landscape →
Q5TGY3	—	0.991	Q5TGY3 →
Q3TY92	—	0.991	Q3TY92 →
Q66HC8	—	0.991	Q66HC8 →
Q86UU5	—	0.991	Q86UU5 →
Q9HCH0	—	0.990	Q9HCH0 →
Q5VV67	—	0.990	Q5VV67 →
GLI1	Zinc finger protein GLI1	0.990	landscape →
Q80U22	—	0.990	Q80U22 →
Q80WJ1	—	0.989	Q80WJ1 →
Q96RK0	—	0.989	Q96RK0 →
Q9P1Z0	—	0.989	Q9P1Z0 →
Q6NZN1	—	0.989	Q6NZN1 →
Q00587	—	0.989	Q00587 →
Q5JPB2	—	0.989	Q5JPB2 →
P17483	—	0.989	P17483 →
Q9D1Z2	—	0.988	Q9D1Z2 →
Q63449	—	0.987	Q63449 →
Q6PAL7	—	0.987	Q6PAL7 →
Q3UHR0	—	0.987	Q3UHR0 →
Q90932	—	0.987	Q90932 →
P47806	—	0.987	P47806 →
Q8N2Y8	—	0.987	Q8N2Y8 →
A2A9I7	—	0.987	A2A9I7 →
A8MZF0	—	0.987	A8MZF0 →
P78412	—	0.987	P78412 →
Q02080	—	0.987	Q02080 →
P70459	—	0.987	P70459 →
A7X8C9	—	0.986	A7X8C9 →